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Intractable epilepsy in children poses a serious medical challenge. Acute repetitive seizures
and status epilepticus leads to frequent emergency room visits and hospital admissions.
Delay of treatment may lead to resistance to the first-line anticonvulsant therapies. It has
been shown that these children continue to remain intractable even after acute seizure
management with approved Food and Drug Administration (FDA) agents. Intravenous leve-
tiracetam, a second-generation anticonvulsant was approved by the FDA in 2006 in patients
16 years and older as an alternative when oral treatment is not an option. Data have been
published showing that intravenous levetiracetam is safe and efficacious, and can be used
in an acute inpatient setting. This current review will discuss the recent data about the
safety and tolerability of intravenous levetiracetam in children and neonates, and empha-
size the need for a larger prospective multicenter trial to prove the efficacy of this agent in
acute seizure management.
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INTRODUCTION
The pediatric epilepsy population is frequently admitted to the
hospital because of status epilepticus or acute repetitive seizures.
Status epilepticus is defined as continuous seizure activity lasting
for 30 min or longer or intermittent seizures lasting for more than
30 min from which the patient does not regain consciousness (1).
The other definition is a continuous seizure lasting at least 5 min,
or two or more seizures without full recovery of consciousness
between seizures lasting at least 5 min or more (2). Acute repeti-
tive seizures are described as seizures that recur over a set period.
These typically last for hours in children and up to 1 or 2 days in
adults (3).
Acute management of seizures is crucial in the prevention
of permanent neurological sequelae. Despite the use of ben-
zodiazepines and first generation anticonvulsants, patients still
remain refractory to treatment, emphasizing the need of newer
anticonvulsants such as levetiracetam.
Levetiracetam is a pyrrolidine-derivative antiepileptic drug,
which is chemically different from all other anticonvulsant agents.
It has a novel mechanism of action, which does not involve
inhibitory and excitatory neurotransmission. Levetiracetam works
by binding SV2A, an integral membrane protein present on
synaptic vesicles, preventing synaptic vesicle release (4). Thereby,
impeding conduction across the synapse. The United States Food
and Drug Administration (FDA) approved intravenous levetirac-
etam in August 2006 for patients above 16 years of age when oral
treatment is not feasible.
Studies have demonstrated that intravenous levetiracetam has
a favorable safety and pharmacokinetic profile as seen with oral
levetiracetam in adult subjects (5, 6). Weinstock et al. conducted
an Open-Label, Single-Arm, Multicenter, Safety, Tolerability, and
Pharmacokinetic Study of Intravenous Levetiracetam in Children
with Epilepsy. The age ranged from 1 month to 16 years of age.
Fifty-two subjects were enrolled. No significant adverse events
were reported and it was well tolerated in this population (7).
Levetiracetam has been found to be effective in certain experi-
mental models of status epilepticus (8, 9). It also has been demon-
strated that intravenous levetiracetam can be used as an alternative
to oral dosing in patients, and data have been published about effi-
cacy and safety in children of different age groups with epilepsy
(10). In this review, we will discuss the literature that has displayed
efficacy of intravenous levetiracetam in children and neonates.
EFFICACY IN NEONATES
Seizures affect approximately 1–5 out of 1000 newborns and 11
out of 1000 preterm neonates (11–13). The most common causes
of neonatal seizures include hypoxic-ischemic encephalopathy,
intracranial hemorrhages, infections of the central nervous sys-
tem, cerebral infarctions, and metabolic disturbances (11, 12).
Protection and prevention of significant adverse effects upon
the developing brain is critical in neonatal period. Phenobarbi-
tal, which acts via GABAergic mechanisms, remains as the most
frequently used antiepileptic drug for the treatment of neonatal
seizures. Current research suggests that the GABA receptor may
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be prone to deficient inhibition in the neonate (11). A muted or
net excitatory affect from the binding of GABA in the neonatal
brain may be due to an increased concentration of chloride in the
immature brain’s neurons (11). Additionally, evidence exists that
phenobarbital causes neuronal apoptosis in animal models, and
long term adverse neurodevelopmental effects related to pheno-
barbital have been demonstrated (14). Several other antiepileptic
drugs are being researched and prescribed in children and neonates
(14, 15). Levetiracetam is increasingly being used as an antiepilep-
tic drug in the neonatal period,and is recognized as an antiepileptic
drug with neuroprotective properties (14, 16). Koppelstäetter et al.
reported on the use of levetiracetam in term and preterm neonates
with rarely observed adverse effects in their analysis of surveys
from neonatologists and pediatric neurologists (17). A study by
Kilicdag et al. demonstrated a significant decrease in the number
of apoptotic neuronal cells in a levetiracetam treated group of rat
pups who underwent a hypoxic-ischemic brain injury (16).
In the only randomized control trial of antiepileptic drugs in
neonates, Painter et al. demonstrated efficacy of seizure cessation
in less than 50% of patients treated with phenobarbital and pheny-
toin. Phenobarbital and phenytoin were used to treat a variety
of neonatal seizure etiologies in these studies, with the majority
of patients having underlying hypoxic-ischemic encephalopathy
(18). Retrospective studies have demonstrated that intravenous
levetiracetam may be efficacious in the management of acute
seizures in neonates when other medications have failed (19, 20).
Abend et al. conducted a retrospective cohort study of 23
neonates in the Newborn Infant Intensive Care Unit with electro-
clinical or electrographic-only confirmed seizures who received
LEV. There were 12 female and 11 males with a mean gestational
age of 38.7± 1.7 weeks. Patients were identified using the elec-
tronic pharmacy database over a 1-year period. IV LEV bolus doses
of 10–20 mg/kg were given to neonates. Next, LEV was adminis-
tered twice per day. LEV effectiveness was defined as a greater than
50% reduction in electrographic seizure within 24 h of the start
of treatment. Neonatal seizure etiologies included eight hypoxic-
ischemic encephalopathy, four presumed genetic/metabolic dis-
orders, three brain malformations, three central nervous sys-
tem infections, two strokes, two cryptogenic seizures, and one
tumor. Seizure types included focal or multifocal clonic or tonic
(18/23), subtle seizures (5/23), and desaturation/apnea (2/23).
LEV was started at a mean age of 41 weeks. The mean ini-
tial dose was 16± 6 mg/kg and the mean maximum dose was
45± 19 mg/kg/day. There were no reported or detected respira-
tory or cardiovascular adverse effects. Greater than 50% seizure
reduction within 24 h was considered to be effective and LEV was
effective in 8 of 23 (35%). Seven of 23 patients had a complete
seizure resolution (19).
Khan et al. performed a retrospective chart review of electronic
medical records for neonates treated with IV LEV between January
2007 and December 2009. The researchers identified 22 neonates
(0–28 days of age) born at term (≥37 weeks) with neonatal seizures
who received IV LEV. Loading doses were from 10 to 50 mg/kg (20
patients received a loading dose of 50 mg/kg). Seizure etiologies
included hypoxic-ischemic encephalopathy (12/22, 55%), hemor-
rhage (2/22, 9%), viral meningoencephalitis (2/22, 9%), and one
patient each with benign neonatal seizures, brain malformation,
cryptogenic partial seizures, glucose transporter protein type 1
deficiency, infarction, and trauma (1/22, 5%). Nineteen of 22
patients (86%) demonstrated immediate seizure cessation within
1 h. After loading dose complete seizure cessation was achieved in
7 of 22 patients (32%), by 24 h in 14 of 22 (64%), by 48 h by 19
of 22 (86%), and by 72 h in all 22 (100%). The authors concluded
that IV LEV can be used in neonates as monotherapy and adjunct
therapy in acute seizure management (20).
Levetiracetam continues to be used in a variety of clinical situa-
tions and seizure etiologies in neonates. Shoemaker and Rotenberg
reported on the successful use of levetiracetam in neonates with
varying seizure etiologies (21). Hmaimess et al. showed the effi-
cacy of levetiracetam in a neonate with intractable malignant
migrating partial seizures (22). Ledet et al. also showed efficacy
as a prophylactic antiseizure medication in a neonate with acute
lymphoblastic leukemia (23).
Furwentsches et al. examined the use of LEV as monotherapy
in the treatment of neonatal seizures in a prospective pilot feasibil-
ity study. The study sample size included six consecutive mature
or premature newborns presenting with neonatal seizures. Exclu-
sion criteria included seizures due to electrolytes or hypoglycemia,
seizures who did respond to pyridoxine, and patients previously
treated with other AEDs. LEV was administered orally over 3 days
with each dose increasing 10 mg/kg/day up to 50 mg/(kg/day).
The study endpoint was either if the patient needed additional
AEDs after day 3 or 3 months of LEV treatment. Seizure semiology
major symptoms include tonic and apnea (3/6 patients, 50%), oral
automatisms, staring and apnea (2/6 patients, 33%), and clonic
and apnea (1/6, 17%). The researchers did not observe any severe
adverse effects, although one infant had mild sedation. Within
6 days, all six patients treated with oral LEV became seizure free.
Three months later, after ongoing LEV monotherapy, five patients
remained seizure free. The remaining patient did not respond to
therapy and developed pharmacoresistant epilepsy (24).
IV LEV was used as a first-line treatment in Ramantani et
al.’s prospective feasibility study. From 2006 to 2008, the study
consisted of 38 consecutively admitted newborns with EEG-
confirmed seizures and excluded seizures due to electrolyte defi-
ciencies and pyridoxine dependency. Nineteen of 38 newborns
were extremely premature at gestational age <28 weeks. Seizure
semiology included subtle, focal clonic, multifocal clonic, focal
tonic, generalized tonic, and myoclonic. Patients<28 weeks gesta-
tional age most commonly had subtle seizure semiology (N = 12,
63%), patients 28–36 weeks most commonly had multifocal clonic
seizures (N = 4, 67%), and patients ≥37 weeks most commonly
had focal clonic seizures (N = 5, 38%). Intravenous doses of
LEV were started at 10 mg/kg and over the course of 3 days were
increased to 30 mg/kg, and at the end of the week were further
titrated to 45–60 mg/kg. When the infant’s condition allowed, IV
LEV was switched to oral administration. Up to two IV doses of
phenobarbital (20 mg/kg) during LEV titration were tolerated for
acute intervention. Acute interventions of one dose of phenobar-
bital was needed in 19 patients and three patients required two
doses. At the conclusion of the first week, 30 infants treated with
LEV were seizures free, while at the end of 4 weeks 27 infants
remained seizure free. Seven infants received LEV for a dura-
tion up to 3 months, but in 19 infants LEV was discontinued
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after 2–4 weeks. There was no report of severe adverse effects.
Ramantani et al. concluded that the results indicated the safety
and efficacy of LEV treatment in neonatal seizures (25).
Pharmacokinetic studies have established a benign safety pro-
file for levetiracetam. Merhar et al. used initial loading doses of
15–40 mg/kg, and demonstrated that levetiracetam was well toler-
ated in 18 neonates with seizures. The only adverse event present
was somnolence. The study also found linear kinetics, minimal
protein binding, and no hepatic metabolism with levetiracetam
use in neonates (26). At this time, there are no clear dosing rec-
ommendations available in the literature where doses range from
10 to 70 mg/kg (15, 19, 20, 26–29).
EFFICACY IN CHILDREN
There have been multiple case reports, case series, and retro-
spective studies reported in children which showed the efficacy
and tolerability of intravenous levetiracetam in acute seizure
management both as adjunctive and monotherapy.
Haberlandt et al. showed the use of levetiracetam in the treat-
ment of two children with myoclonic status epilepticus (30).
Alehan et al. contributed a case report to the literature supporting
the use of levetiracetam in children with non-convulsive status
epilepticus (31). Weber et al. showed efficacy of levetiracetam in
a child with Angelman syndrome presenting in non-convulsive
status epilepticus (32). Cilio et al. showed the termination of
refractory status epilepticus in two patients with migrating partial
seizures in infancy with intravenous levetiracetam (27).
Michaelides et al. performed a retrospective analysis of a pedi-
atric population under the age of 14 on the use of IV formulation
of LEV for in its first 9 months of availability in their institution.
The researchers reviewed the paper and electronic medical records
of 15 children ≤14 years of age (3 months–14 years) who received
IV LEV in the first 9 months that it was available at the institu-
tion. Seizure etiologies included six patients had complex partial
seizures, three had generalized tonic-clonic, two no seizure type
only for prophylaxis, one myoclonic, one tonic, and one mixed.
Over the 9 months there were 118 infusions performed in 15
patients. No adverse reactions were observed. Nine minor adverse
reactions were observed during the rest of the hospitalization that
were potentially related to the IV formulation: three of these were
decreases in WBC count, and six were behavioral adverse effects. In
LEV naïve patients (N = 7) the median starting dose was 8.8 mg/kg
(range: 5.0–50), and all patients had a median maintenance dose of
30.4 mg/kg/day (5.0–92). There were six patients in a subgroup less
than 4 years old (avg.= 1 year 4 months), who received the major-
ity of the LEV infusions in the entire study population (82/118
total infusions). Of the 15 patients, five had very frequent seizures
(two with status epilepticus) and three of these patients had a
seizure frequency reduction of >50%. One patient had complete
seizure resolution. Michaelides et al. concluded that IV LEV was
very well tolerated in their pediatric population (28).
Goraya et al. retrospectively identified 10 patients (aged
3 weeks–19 years) through their hospital pharmacy records all
patients who received intravenous levetiracetam. Forty percent
of patients had received IV levetiracetam for acute repetitive
seizures/status epilepticus, 30% presented on levetiracetam, 10%
received IV LEV for seizure prophylaxis for a brain biopsy, 10%
received it for severe thrombocytopenia, and 10% for an acute
symptomatic seizure. The dosages of IV LEV used varied accord-
ing to the indication for usage: replacement of oral LEV used a
mg for mg substitution, for status epileptics 20–40 mg/kg/dose
was used every 8 h for infants or 12 h for older children, and for
maintenance treatment after biopsy a dose of 10–20 mg/kg every
12 h was used and was given as an infusion. Seventy-five percent
of the patients who received IV LEV for control of status epilep-
ticus (three of four) became seizure free and 25% (one of four)
had a>50% reduction in seizure frequency. This neonatal patient
became seizure free on IV LEV after an area of cortical dysplastic
tissue that had been found was removed. None of the 10 patients
had any adverse events noted during IV LEV usage and there was
no discontinuation of IV LEV due to side effects (29).
Kirmani et al. retrospectively reviewed 32 pediatric patients
from 2 months to 18 years of age. The sample size included 53.1%
males and 46.8% females. Data were acquired from electronic
medical records for patients admitted in the hospital with sta-
tus epilepticus or acute exacerbation of seizure patients who
received intravenous levetiracetam. The loading dose used was
25–50 mg/kg. Data analysis showed a favorable response to intra-
venous levetiracetam for all patients and seizures were aborted
both clinically and electrographically. In 18 patients, intravenous
levetiracetam was infused after fosphenytoin and lorazepam. No
serious side effects were reported in all subjects. Fifteen patients
were discharged on levetiracetam monotherapy and nine on
adjunctive therapy. The study concluded that intravenous leve-
tiracetam was found to be efficacious both in status epilepticus
and acute exacerbation of seizures (33).
Abend et al. described a cohort of critically ill children who
received intravenous levetiracetam for status epilepticus or acute
repetitive seizures. All the subjects responded to intravenous lev-
etiracetam resulting in either termination, temporary cessation,
or reduction in ongoing seizure activity (34). Khurana et al. con-
ducted a retrospective analysis at a single institution over a period
of 3 years. Their group identified 81 patients, in which 18 of them
received levetiracetam as monotherapy. Fourteen patients had par-
tial epilepsy and four had generalized epilepsy. The dose range was
14–60 mg/kg,and duration of therapy ranged from 2 to 24 months.
The study concluded that levetiracetam was found to be efficacious
as monotherapy in the management of pediatric epilepsy (35).
Gallentine et al. conducted a retrospective analysis over a 7-year
period. Eleven children had received levetiracetam for refractory
status epilepticus with the age ranging from 2 days to 9 years. The
patients were treated with two to seven anticonvulsants prior to
infusion of levetiracetam. Levetiracetam was found to be effica-
cious in 45% of cases, resulting in resolution of refractory status
epilepticus. The median latency to resolution of status epilepticus
following initiation of levetiracetam was 1.5 days. The respond-
ing subjects received a median dose 40 mg/kg/day. No significant
adverse effects were reported. The authors concluded that leve-
tiracetam was safe to use as adjuvant therapy in children with
refractory status epilepticus (36).
Pharmacokinetic studies have established a benign safety pro-
file for levetiracetam. Li et al. demonstrated that levetiracetam
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is a safe and effective treatment for infants and children in an
observational, prospective study Li et al. prospectively analyzed
120 patients (39.3% female, 61.7% male) with epilepsy receiv-
ing mono or combination therapy with levetiracetam that were
14-year-old and younger. Therapy was started with a levetirac-
etam dose of 10 mg/kg/day and if seizures were poorly controlled
titrated up with 10 mg/kg increments to a maximum daily dose of
60 mg/kg/day. They documented seizure type, seizure frequency,
levetiracetam dose, and side effects. Li et al. found that the 83.0%
of the study population had a seizure reduction of at least 50%,
and 54.8% of patients were seizure free. There was a side effect
incidence rate of 47.5%, and included somnolence, dysphoria, ner-
vousness, dystrophy, somnipathy, astitia, and debilitation. There
was a 3.3% patient withdrawal rate most commonly due to poor
effect or intolerance of side effects. The researchers concluded
that levetiracetam was safe and effective for epileptic children with
multiple types of epileptic seizures (37).
CONCLUSION
Linear kinetics, minimal protein binding, and no hepatic metabo-
lism with levetiracetam use in children and neonates, and favorable
response in status epilepticus and repetitive seizures makes leve-
tiracetam a suitable choice in acute seizure management in both
children and neonates. However, larger prospective, randomized,
blind comparison trials between phenobarbital, levetiracetam, and
phenytoin would provide more information regarding the use of
this newer agent in acute management of seizures in the pediatric
population.
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